Jovana J. Ajduković

HIF-1 — A BIG CHAPTER IN THE CANCER TALE

Jovana J. Ajduković · Experimental Oncology · 2016 · 52 citations

Evaluation of A-ring fused pyridine <scp>d</scp>-modified androstane derivatives for antiproliferative and aldo–keto reductase 1C3 inhibitory activity

Marina P. Savić, Jovana J. Ajduković, Jovana J. Plavša et al. · MedChemComm · 2018 · 42 citations · Full text

17(E)-Picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: Antiproliferative activity and molecular docking studies

Jovana J. Ajduković, Evgenija A. Djurendić, Edward T. Petri et al. · Bioorganic & Medicinal Chemistry · 2013 · 35 citations

Molecular Pharmacology, Medicinal Chemistry, Molecular Docking Studies +10

Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives

Evgenija A. Djurendić, Jovana J. Ajduković, Marija N. Sakač et al. · European Journal of Medicinal Chemistry · 2012 · 30 citations

Derivative (Chemistry), Biochemistry, Cytotoxic Activity +4

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor

Nenad Ignjatović, Katarina Penov‐Gasi, Victoria Wu et al. · Colloids and Surfaces B Biointerfaces · 2016 · 30 citations · Full text

Nanomedicine, Medicinal Chemistry, Selective Anticancer Activity +8